{
  "abstract": "BACKGROUND: Evidence to guide (neo)adjuvant chemotherapy choices in carriers of germline BRCA1/BRCA2 pathogenic variants (BRCA carriers) with early breast cancer (BC) is limited. We evaluated the association of different chemotherapy regimens with survival outcomes in this population. METHODS: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, retrospective cohort study of BRCA carriers diagnosed with stage I-III BC at age ≤ 40 years, between 2000 and 2020. Disease-free survival (DFS) and overall survival (OS) were assessed among patients with HER2-negative disease treated with anthracycline-taxane, anthracycline-no-taxane, or non-anthracycline (neo)adjuvant chemotherapy. The association of platinum use with outcomes was evaluated in triple-negative breast cancer (TNBC). RESULTS: Among 4200 young BRCA carriers from 109 centres who received (neo)adjuvant chemotherapy for HER2-negative BC, 58.7% had TNBC. Median follow-up was 8.1 years (IQR, 4.7-12.6 years). Anthracycline-taxane, anthracycline-no-taxane, and non-anthracycline regimens were used in 74.4%, 19.3%, and 6.3% of patients, respectively. Platinum agents were administered in 19.8% of TNBC cases. After multivariable adjustment, no significant differences in DFS or OS were observed between anthracycline-no-taxane and anthracycline-taxane regimens (DFS adjusted hazard ratio [aHR] 0.88, 95% CI 0.73-1.05; OS aHR 1.20, 95% CI 0.87-1.67) or non-anthracycline regimens (DFS aHR 1.07, 95% CI 0.82-1.38; OS aHR 1.16, 95% CI 0.68-2.0). In TNBC, platinum use was not associated with improved outcomes. CONCLUSIONS: In young BRCA carriers with HER2-negative early BC, no statistically significant differences in survival outcomes were detected across different chemotherapy regimens. Our findings may inform future prospective studies evaluating chemotherapy de-escalation strategies in this genetically defined population.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 48,
  "authors": [
    {
      "name": "Rinat Bernstein-Molho"
    },
    {
      "name": "Tal Sella"
    },
    {
      "name": "Virginia Delucchi"
    },
    {
      "name": "Florence Coussy"
    },
    {
      "name": "Hee Jeong Kim"
    },
    {
      "name": "Sabine Linn"
    },
    {
      "name": "Antonio Di Meglio"
    },
    {
      "name": "Katarzyna Pogoda"
    },
    {
      "name": "Ava Kwong"
    },
    {
      "name": "Elisa Agostinetto"
    },
    {
      "name": "Jyoti Bajpai"
    },
    {
      "name": "Yannick van Herck"
    },
    {
      "name": "Alberta Ferrari"
    },
    {
      "name": "Judith Balmana"
    },
    {
      "name": "Halle Moore"
    },
    {
      "name": "Fedro Peccatori"
    },
    {
      "name": "Ann Partridge"
    },
    {
      "name": "Melina Winocur"
    },
    {
      "name": "Tiphaine Renaud"
    },
    {
      "name": "Christine Rousset-Jablonski"
    },
    {
      "name": "Jeong Eon Lee"
    },
    {
      "name": "Angela Toss"
    },
    {
      "name": "Shani Paluch-Shimon"
    },
    {
      "name": "Stephanie Wong"
    },
    {
      "name": "Alexios Matikas"
    },
    {
      "name": "Cynthia Villarreal-Garza"
    },
    {
      "name": "Claudio Vernieri"
    },
    {
      "name": "Minna Lee"
    },
    {
      "name": "Deniz Can Guven"
    },
    {
      "name": "Wanda Cui"
    },
    {
      "name": "Kathryn Ruddy"
    },
    {
      "name": "Maria Vittoria Dieci"
    },
    {
      "name": "Robert Fruscio"
    },
    {
      "name": "Laura de Marchis"
    },
    {
      "name": "Zoe Kemp"
    },
    {
      "name": "Pedro Meireles"
    },
    {
      "name": "Maria Grazia Razeti"
    },
    {
      "name": "Maria del Pilar Diz"
    },
    {
      "name": "Shelley Hwang"
    },
    {
      "name": "Fabio Puglisi"
    },
    {
      "name": "Florian Clatot"
    },
    {
      "name": "Rinat Yerushalmi"
    },
    {
      "name": "Natalia Cichowska-Cwalinska"
    },
    {
      "name": "Alessandra Chirco"
    },
    {
      "name": "Carmine de Angelis"
    },
    {
      "name": "Eva Blondeaux"
    },
    {
      "name": "Matteo Lambertini"
    },
    {
      "name": "Halle C.F. Moore"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c0wbhmes7t7v9.bib",
  "cited_by": 0,
  "doi": "10.1016/j.ejca.2026.116937",
  "fulltext_url": null,
  "id": "c0wbhmes7t7v9",
  "issns": [
    "0959-8049"
  ],
  "landing_url": "https://hal.science/hal-05750637v1",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.spee"
    ],
    [
      "openalex",
      "1311|BRCA gene mutations in cancer"
    ]
  ],
  "openalex": "W7168265486",
  "pdf_url": "https://www.ejcancer.com/article/S0959-8049(26)00718-5/pdf",
  "pmcid": null,
  "pmid": "42580099",
  "published": "2026-09-15",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/c0wbhmes7t7v9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:34Z",
      "native_id": "hal-05750637",
      "source": "hal",
      "url": "https://hal.science/hal-05750637v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.spee",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer",
  "title_text": "Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:34Z",
  "url": "https://research.draconitic.com/paper/c0wbhmes7t7v9",
  "venue": "European Journal of Cancer",
  "versions": []
}